ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 1 مورد

Tedizolid: Drug information

Tedizolid: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Tedizolid: Patient drug information" and "Tedizolid: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Sivextro
Pharmacologic Category
  • Antibiotic, Oxazolidinone
Dosing: Adult
Mycobacterial infection

Mycobacterial (nontuberculous, rapidly growing) infection (off-label use):

Note: Patients should be under the care of a clinician with expertise in managing mycobacterial infection (Ref).

Oral, IV: 200 mg once daily as part of an appropriate combination regimen (Ref).

Skin and soft tissue infection

Skin and soft tissue infection (alternative agent):

Note: Reserve for patients with or at risk for methicillin-resistant S. aureus infection who cannot receive preferred agents (Ref).

Oral, IV: 200 mg once daily (Moran 2014; Prokocimer 2013). Total duration of therapy is ≥5 days; may extend up to 14 days depending on severity and clinical response (Ref).

Missed doses: Administer as soon as possible any time up to 8 hours prior to the next scheduled dose; if less than 8 hours remain before the next dose, wait until the next scheduled dose.

Dosing: Kidney Impairment: Adult

No dosage adjustment necessary.

Dosing: Liver Impairment: Adult

No dosage adjustment necessary.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Tedizolid: Pediatric drug information")

Dosage guidance:

Safety: Dosages are presented in mg/kg/dose and flat mg doses depending on patient weight; use caution.

Skin and soft tissue infection

Skin and soft tissue infection:

Infants, Children, and Adolescents:

IV:

1 to <2 kg: IV: 3 mg/kg/dose every 12 hours for 6 days.

2 to <3 kg: IV: 6 mg every 12 hours for 6 days.

3 to <6 kg: IV: 12 mg every 12 hours for 6 days.

6 to <10 kg: IV: 20 mg every 12 hours for 6 days.

10 to <14 kg: IV: 30 mg every 12 hours for 6 days.

14 to <20 kg: IV: 40 mg every 12 hours for 6 days.

20 to <35 kg: IV: 60 mg every 12 hours for 6 days.

≥35 kg: IV: 200 mg once daily for 6 days (Ref).

Oral: Children and Adolescents weighing ≥35 kg: Oral: 200 mg once daily for 6 days (Ref).

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: Any degree of kidney impairment or patients receiving hemodialysis: Oral, IV: No dosage adjustment necessary; not removed by hemodialysis.

Dosing: Liver Impairment: Pediatric

Infants, Children, and Adolescents: Oral, IV: No dosage adjustment necessary.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise specified.

1% to 10%:

Cardiovascular: Flushing (<2%), hypertension (<2%), palpitations (<2%), phlebitis (children, adolescents: 3%), tachycardia (<2%)

Dermatologic: Dermatitis (<2%), pruritus (<2%), urticaria (<2%)

Gastrointestinal: Clostridioides difficile colitis (<2%), diarrhea (4%), nausea (7%), oral candidiasis (<2%), vomiting (adolescents, adults: 1% to 3%)

Genitourinary: Vulvovaginal infection (fungal: <2%)

Hematologic & oncologic: Anemia (children, adolescents, adults: <2%), decreased platelet count (<112,000/mm3: children, adolescents, adults: 1% to 2%), decreased white blood cell count (<2%)

Hepatic: Increased gamma-glutamyl transferase (<2%), increased serum alanine aminotransferase (children, adolescents, adults: ≤3%), increased serum aspartate aminotransferase (children, adolescents, adults: ≤3%)

Hypersensitivity: Hypersensitivity reaction (<2%), infusion-related reaction (≤4%)

Local: Injection-site reaction (≤4%)

Nervous system: Dizziness (2%), facial nerve paralysis (<2%), headache (5%), hypoesthesia (<2%), insomnia (<2%), paresthesia (<2%), peripheral neuropathy (1%)

Ophthalmic: Asthenopia (<2%), blurred vision (<2%), visual impairment (<2%), vitreous opacity (<2%)

<1%:

Hematologic & oncologic: Decrease in absolute neutrophil count (<800/mm3)

Ophthalmic: Optic neuropathy

Postmarketing: Hematologic & oncologic: Thrombocytopenia

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Concerns related to adverse effects:

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Neutropenia: Not recommended for use in patients with neutrophil counts <1000 cells/mm3. Alternative therapies should be considered when treating patients with neutropenia and acute bacterial skin and skin structure infections (ABSSI).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous, as phosphate [preservative free]:

Sivextro: 200 mg (1 ea)

Tablet, Oral, as phosphate:

Sivextro: 200 mg

Generic Equivalent Available: US

No

Pricing: US

Solution (reconstituted) (Sivextro Intravenous)

200 mg (per each): $444.58

Tablets (Sivextro Oral)

200 mg (per each): $558.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: Administer with or without food.

Intravenous: Administer as an IV infusion over 1 hour; do not administer as an IV push or bolus. Not for intra-arterial, IM, intrathecal, intraperitoneal, or subcutaneous administration. If the same IV line is to be used for sequential infusion of other drugs or solutions, the line should be flushed with NS before and after tedizolid infusion.

Administration: Pediatric

Oral: Administer with or without food.

Missed dose: Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose. All prescribed doses should be administered even if a dose is missed.

Parenteral: IV: Administer as an IV infusion over 1 hour; do not administer as an IV push or bolus. Not for intra-arterial, IM, intrathecal, intraperitoneal, or SUBQ administration. If the same IV line is to be used for sequential infusion of other drugs or solutions, the line should be flushed with NS before and after tedizolid infusion.

Usual Infusion Concentrations: Adult

200 mg in 250 mL (concentration: 0.8 mg/mL) of NS only

Use: Labeled Indications

Skin and soft tissue infections: Treatment of adults and pediatric patients ≥26 weeks GA and ≥1 kg with acute bacterial skin and soft tissue infections caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

Use: Off-Label: Adult

Mycobacterial (nontuberculous, rapidly growing) infection

Metabolism/Transport Effects

Inhibits BCRP;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpelisib: BCRP/ABCG2 Inhibitors may increase serum concentration of Alpelisib. Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions. Risk D: Consider Therapy Modification

Amifampridine: Agents With Seizure Threshold Lowering Potential may increase neuroexcitatory and/or seizure-potentiating effects of Amifampridine. Risk C: Monitor

Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor

ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor

ARIPiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Asenapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification

BCG (Intravesical): Antibiotics may decrease therapeutic effects of BCG (Intravesical). Risk X: Avoid

BCG Vaccine (Immunization): Antibiotics may decrease therapeutic effects of BCG Vaccine (Immunization). Risk C: Monitor

BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Tedizolid may increase serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Benperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Blonanserin: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Blonanserin. Specifically, the risk of seizures may be increased. Risk C: Monitor

Brexpiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Bromperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Bromperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

BuPROPion: May increase neuroexcitatory and/or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor

Cariprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ChlorproMAZINE. Specifically, the risk of seizures may be increased. Risk C: Monitor

Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid

Cladribine: BCRP/ABCG2 Inhibitors may increase serum concentration of Cladribine. Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration. Risk D: Consider Therapy Modification

Clothiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

CloZAPine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Risk C: Monitor

DroPERidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of DroPERidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Fecal Microbiota (Live) (Oral): May decrease therapeutic effects of Antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid

Flupentixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor

FluPHENAZine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Haloperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Iloperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Iohexol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor

Loxapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Lumateperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Lurasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Methotrimeprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Molindone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor

OLANZapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of OLANZapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Paliperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

PAZOPanib: BCRP/ABCG2 Inhibitors may increase serum concentration of PAZOPanib. Risk X: Avoid

Periciazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Perphenazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pimozide: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pimozide. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pipamperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pipamperone. Specifically, the risk of seizures may be increased. Risk X: Avoid

Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor

Prochlorperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Promazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

QUEtiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of QUEtiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

RisperiDONE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor

Seladelpar: BCRP/ABCG2 Inhibitors may increase serum concentration of Seladelpar. Risk C: Monitor

Sertindole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sertindole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor

Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification

Sulpiride: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sulpiride. Specifically, the risk of seizures may be increased. Risk C: Monitor

Sympathomimetics: Tedizolid may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor

Talazoparib: BCRP/ABCG2 Inhibitors may increase serum concentration of Talazoparib. Risk C: Monitor

Thioridazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thioridazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Thiothixene: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor

Topotecan: BCRP/ABCG2 Inhibitors may increase serum concentration of Topotecan. Risk X: Avoid

Trifluoperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification

Ubrogepant: BCRP/ABCG2 Inhibitors may increase serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor. Risk D: Consider Therapy Modification

Ziprasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pregnancy Considerations

Adverse events were observed in animal reproduction studies.

Breastfeeding Considerations

It is not known if tedizolid is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

Baseline complete blood count (CBC) with differential

Mechanism of Action

After conversion from the prodrug, tedizolid phosphate, tedizolid binds to the 50S bacterial ribosomal subunit. This prevents the formation of a functional 70S initiation complex that is essential for the bacterial translation process and subsequently inhibits protein synthesis. Tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci (Kisgen 2014).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral: Well absorbed.

Distribution:

Children 2 to <6 years: Vd: Single dose: Geometric mean range: 20.4 to 20.5 L (Arrieta 2021).

Children 6 to <12 years: Vd: Single dose: Geometric mean range: 29.4 to 31.1 L (Arrieta 2021).

Children ≥12 years and Adolescents ≤17 years (mean weight: 55.3 kg): Vdss: 54.2 ± 10.2 L (Bradley 2016).

Adults: Vdss: 67 to 80 L.

Protein binding: 70% to 90%.

Metabolism: Tedizolid phosphate is converted by phosphatases to tedizolid (active, parent drug); no other significant circulating metabolites.

Bioavailability: Oral: ~91%.

Half-life elimination:

Children 2 to <6 years: IV: Geometric mean range: 5.51 to 5.76 hours (Arrieta 2021).

Children 6 to <12 years: IV: Geometric mean range: 4.93 to 5.18 hours (Arrieta 2021).

Children ≥12 years and Adolescents ≤17 years: IV, Oral: 6.64 to 8.26 hours (Bradley 2016).

Adults: ~12 hours.

Time to peak: Oral: ~3 hours; IV: 1 to 1.5 hours.

Excretion: Feces (82%) and urine (18%), both as inactive sulfate conjugates. Less than 3% excreted in feces or urine as parent drug.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy:

S. aureus: fAUC24/minimum inhibitory concentration; goal: ~20 to 50 (bacteriostasis); ~35 to 105 (1-log kill) (Lepak 2012; Louie 2011).

Expected drug exposure in patients with normal renal function:

Cmax (peak):

Single dose, 200 mg:

Adolescents 12 to 17 years of age: Oral: 2.23 ± 0.55 mg/L; IV: 3.85 ± 1.51 mg/L (Bradley 2016).

Adults, BMI <30 kg/m2: Oral: 2.3 mg/L; IV: 2.9 mg/L (Flanagan 2017).

Adults, BMI ≥30 kg/m2: Oral: 1.9 mg/L; IV: 2.5 mg/L (Flanagan 2017).

Multiple dose (steady state):

Neonates (GA ≥26 weeks), Infants, Children, and Adolescents <18 years:

1 to <2 kg: IV: 3 mg/kg/dose every 12 hours: Geometric mean: 2.3 mg/L.

2 to <3 kg: IV: 6 mg every 12 hours: Geometric mean: 1.8 mg/L.

3 to <6 kg: IV: 12 mg every 12 hours: Geometric mean: 2.4 mg/L.

6 to <10 kg: IV: 20 mg every 12 hours: Geometric mean: 2.2 mg/L.

10 to <14 kg: IV: 30 mg every 12 hours: Geometric mean: 2.7 mg/L.

14 to <20 kg: IV: 40 mg every 12 hours: Geometric mean: 2.7 mg/L.

20 to <35 kg: IV: 60 mg every 12 hours: Geometric mean: 2.6 mg/L.

≥35 kg: 200 mg once daily: Geometric mean: IV: 3.8 mg/L; Oral: 2.5 mg/L.

Adults: 200 mg once daily: Oral: 2.2 ± 0.6 mg/L; IV: 3 ± 0.7 mg/L.

AUC:

Single dose, 200 mg: AUC0 to ∞:

Adolescents 12 to 17 years of age: Oral: 25.2 ± 9.2 mg•hour/L; IV: 27.8 ± 7.3 mg•hour/L (Bradley 2016).

Adults, BMI <30 kg/m2: Oral: 28.5 mg•hour/L; IV: 28.7 mg•hour/L (Flanagan 2017).

Adults, BMI ≥30 kg/m2: Oral: 25.4 mg•hour/L; IV: 25.4 mg•hour/L (Flanagan 2017).

Multiple dose (steady state): AUC24:

Neonates (GA ≥26 weeks), Infants, Children, and Adolescents <18 years:

1 to <2 kg: IV: 3 mg/kg/dose every 12 hours: Geometric mean: 33.1 mg•hour/L.

2 to <3 kg: IV: 6 mg every 12 hours: Geometric mean: 20.8 mg•hour/L.

3 to <6 kg: IV: 12 mg every 12 hours: Geometric mean: 26.4 mg•hour/L.

6 to <10 kg: IV: 20 mg every 12 hours: Geometric mean: 22.5 mg•hour/L.

10 to <14 kg: IV: 30 mg every 12 hours: Geometric mean: 27.6 mg•hour/L.

14 to <20 kg: IV: 40 mg every 12 hours: Geometric mean: 28.4 mg•hour/L.

20 to <35 kg: IV: 60 mg every 12 hours: Geometric mean: 31.4 mg•hour/L.

≥35 kg: 200 mg once daily: Geometric mean: IV: 30.6 mg•hour/L; Oral: 29.3 mg•hour/L.

Adults: 200 mg once daily: Oral: 25.6 ± 8.5 mg•hour/L; IV: 29.2 ± 6.2 mg•hour/L.

Postantibiotic effect: Staphylococcus spp. (including methicillin-resistant): 0.05 to 0.7 hours; Enterococcus spp. (including vancomycin-resistant): 0.1 to 1.3 hours (Locke 2014).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Sivextro;
  • (AT) Austria: Sivextro;
  • (BD) Bangladesh: Celutis | Tezolid | Tezolin;
  • (BR) Brazil: Sivextro;
  • (CH) Switzerland: Sivextro;
  • (CO) Colombia: Sivextro;
  • (DE) Germany: Sivextro;
  • (EG) Egypt: Cubizolid | Tedimerp | Zolidocyrl;
  • (ES) Spain: Sivextro;
  • (FI) Finland: Sivextro;
  • (FR) France: Sivextro;
  • (GB) United Kingdom: Sivextro;
  • (GR) Greece: Sivextro;
  • (HU) Hungary: Sivextro;
  • (IE) Ireland: Sivextro;
  • (IT) Italy: Sivextro;
  • (JP) Japan: Sivextro;
  • (KR) Korea, Republic of: Sivextro;
  • (MX) Mexico: Sivextro;
  • (MY) Malaysia: Sivextro;
  • (NL) Netherlands: Sivextro;
  • (NO) Norway: Sivextro;
  • (PH) Philippines: Sivextro;
  • (PL) Poland: Sivextro;
  • (PR) Puerto Rico: Sivextro;
  • (QA) Qatar: Sivextro;
  • (RO) Romania: Sivextro;
  • (RU) Russian Federation: Sivextro;
  • (SA) Saudi Arabia: Sivextro;
  • (SE) Sweden: Sivextro;
  • (SG) Singapore: Sivextro;
  • (SI) Slovenia: Sivextro
  1. Arrieta AC, Ang JY, Espinosa C, et al. Pharmacokinetics and safety of single-dose tedizolid phosphate in children 2 to <12 years of age. Pediatr Infect Dis J. 2021;40(4):317-323. doi:10.1097/INF.0000000000003030 [PubMed 33710976]
  2. Bradley JS, Antadze T, Ninov B, et al. Safety and efficacy of oral and/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections. Pediatr Infect Dis J. 2021;40(3):238-244. doi:10.1097/INF.0000000000003010 [PubMed 33395210]
  3. Bradley JS, Flanagan SD, Arrieta AC, Jacobs R, Capparelli E, Prokocimer P. Pharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescents. Pediatr Infect Dis J. 2016;35(6):628-633. doi:10.1097/INF.0000000000001096 [PubMed 26910588]
  4. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125 [PubMed 32797222]
  5. Flanagan SD, Bien PA, Munoz KA, et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food and comparison of two solid forms of the prodrug. Pharmacother. 2014;34:240-250. [PubMed 23926058]
  6. Flanagan S, Minassian SL, Passarell JA, Fiedler-Kelly J, Prokocimer P. Pharmacokinetics of tedizolid in obese and nonobese subjects. J Clin Pharmacol. 2017;57(10):1290-1294. doi:10.1002/jcph.928 [PubMed 28510339]
  7. Kisgen JJ, Mansour H, Unger NR, et al. Tedizolid: a new oxazolidinone antimicrobial. Am J Health-Sys Pharm. 2014;71:621-633. [PubMed 24688035]
  8. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother. 2012;56(11):5916-5922. doi:10.1128/AAC.01303-12 [PubMed 22964254]
  9. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014;58(suppl 1):S35-S42. doi:10.1093/cid/cit616 [PubMed 24343830]
  10. Longworth SA, Daly JS; AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13588. doi:10.1111/ctr.13588 [PubMed 31077618]
  11. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother. 2011;55(7):3453-3460. doi:10.1128/AAC.01565-10 [PubMed 21502615]
  12. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696-705. doi:10.1016/S1473-3099(14)70737-6 [PubMed 24909499]
  13. O’Riordan WO, Green S, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Inf Dis. 2014;58(S1):S43-50. [PubMed 24343832]
  14. Poon YK, La Hoz RM, Hynan LS, Sanders J, Monogue ML. Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients. Open Forum Infect Dis. 2021;8(4):ofab093. doi:10.1093/ofid/ofab093 [PubMed 33884276]
  15. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose ranging study evaluating the safety, tolerability, population pharmacokinetics and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011;55:583-592. [PubMed 21115795]
  16. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections. The ESTABLISH-1 randomized trial. JAMA. 2013;309:559-569. [PubMed 23403680]
  17. Refer to manufacturer's labeling.
  18. Sivextro (tedizolid) for injection [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; April 2025.
  19. Sivextro (tedizolid) tablet [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; April 2025.
  20. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.
  21. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  22. Urbina O, Ferrandez O, Espona M, et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Design Dev and Ther. 2013;7:243-265. [PubMed 23589680]
Topic 96001 Version 228.0